Gensulin M30

2023: Product Announcement

In early July 2023, the Russian pharmaceutical company Farmasintez announced the production of recombinant human insulins (general insulins) - Gensulin M30, Gensulin H, Gensulin P. Their production was established at the Farmasintez Nord site in St. Petersburg.

The capacity of this plant for the creation of insulins exceeds 5 million units of products per year. Available release forms - vials, disposable syringe pens, as well as cartridges for reusable syringe pens, specified in the press service of the company.

Pharmasinthesis announces release of recombinant human insulins

In the fall of 2023, Farmasintez also plans to launch the production of analog insulins: glargine insulin and lispro insulin, developed jointly with the Chinese companies Gan & Lee Pharmaceuticals. Thus, the Russian company will be able to comprehensively solve the important task of providing Russian patients with high-quality Russian analogues of vital and essential drugs.

Pharmasintez-Nord JSC was among the three residents of the St. Petersburg Special Economic Zone (SEZ) who invested the most in the first quarter of 2023. In the first three months of 2023, the volume of investments in the SEZ increased to 2.9 billion rubles, which is 25% more than in the same period in 2022.

Pharmasintez-Nord is a pharmaceutical research and production complex specializing in the development and production of modern drugs for the treatment of cancer, autoimmune diseases, as well as diseases of the endocrine system. By July 2023, 45 trade names of oncological drugs are produced at the Pharmasintez-Nord site, 99% of which are included in the list of vital and essential drugs. Ministry of Health Russia^[1]

Notes